Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026
Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease

Fineline Cube Apr 1, 2026
Company Drug

Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy

Fineline Cube Apr 1, 2026
Company Deals

Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation

Fineline Cube Nov 28, 2025

Jiangsu Trulive Medical announced the completion of a Series C financing round raising over RMB...

Company Drug

Boan Biotech’s Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases

Fineline Cube Nov 27, 2025

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that its self‑developed Aflibercept Intravitreal Injection (Boyoujing)...

Company Deals

Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront

Fineline Cube Nov 27, 2025

Sprint Bioscience AB announced the sale of its TREX1 cancer program to Gilead Sciences, Inc....

Company Drug

Novo Nordisk’s Semaglutide 7.2 mg sNDA Submitted for Weight Management

Fineline Cube Nov 27, 2025

Novo Nordisk A/S (NYSE: NVO) announced the submission of a supplemental New Drug Application (sNDA)...

Company Drug

CSPC’s JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management

Fineline Cube Nov 27, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self‑developed recombinant fully human anti‑ActRIIA/IIB monoclonal...

Company Medical Device

MicroTech’s LinX CGM Wins India Approval, Expanding Asia Diabetes Monitoring

Fineline Cube Nov 27, 2025

MicroTech Medical (Hangzhou) Co., Ltd. (HKG: 2235) announced that its LinX Continuous Glucose Monitoring (CGM)...

Medical Device

Bio-heart’s IberiRDN Wins New Zealand Nod as Only Dual-Approach Renal Denervation System

Fineline Cube Nov 27, 2025

Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced that its Iberis Multi-Electrode Renal Denervation...

Company Drug

IASO-Bio’s Fucaso Wins Hong-Kong Approval as First China CAR-T

Fineline Cube Nov 27, 2025

IASO Biotherapeutics announced that Fucaso (equecabtagene autoleucel injection), its proprietary fully human BCMA‑targeted CAR‑T cell...

Company Drug

BeOne’s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma

Fineline Cube Nov 27, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that the U.S. FDA has accepted its...

Company Deals

Patronus Biotech Gates Foundation Grant Accelerates Malaria Vaccine Development

Fineline Cube Nov 27, 2025

Patronus Biotech Pte. Ltd. announced it has received a grant from the Gates Foundation to...

Company Deals

Innova Therapeutics Acquires Enci Therapeutics’ IVT-8086 Cancer Program

Fineline Cube Nov 27, 2025

Innova Therapeutics announced the acquisition of Enci Therapeutics, gaining its primary cancer therapeutic program IVT‑8086,...

Company Drug

Gene Key’s iNKT Cell Therapy Wins NMPA Nod for ARDS, First Allogeneic Ready-to-Use

Fineline Cube Nov 27, 2025

Beijing Gene Key Life Technology Co., Ltd. announced that its GKL‑006RTU Injection, China’s first novel...

Company Drug

SciClone’s Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect

Fineline Cube Nov 27, 2025

SciClone Pharmaceuticals Inc. announced that Meropenem/Vaborbactam for Injection has been approved under the “Hong Kong-Macau...

Company Drug

Novartis’ Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria

Fineline Cube Nov 26, 2025

Novartis AG (NYSE: NVS) announced that remibrutinib tablets received National Medical Products Administration (NMPA) approval...

Policy / Regulatory

CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%

Fineline Cube Nov 26, 2025

The U.S. Centers for Medicare & Medicaid Services (CMS) announced results of the second round...

Company Drug

Hengrui’s Three Oncology Assets Win NMPA Clinical Trial Approval

Fineline Cube Nov 26, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that three of its investigational...

Company Drug

Humanwell’s Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential

Fineline Cube Nov 26, 2025

Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA)...

Company Drug

Innovent’s mazdutide 9mg Obesity Application Accepted by NMPA

Fineline Cube Nov 26, 2025

Innovent Biologics, Inc. (HKG: 1801) announced that China’s National Medical Products Administration (NMPA) has accepted...

Company Drug

Fosun’s Luvometinib Gets NMPA Priority Review for Pediatric LCH

Fineline Cube Nov 26, 2025

Fosun Pharma (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has...

Company Deals

Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma

Fineline Cube Nov 26, 2025

Kelonia Therapeutics announced a strategic collaboration with Johnson & Johnson (J&J, NYSE: JNJ) to develop...

Posts pagination

1 … 53 54 55 … 644

Recent updates

  • Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease
  • Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition
  • Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform
  • Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy
  • AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease

Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Company Drug

Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.